Last reviewed · How we verify
China Resources Zizhu Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Mifepristone tablets | Mifepristone tablets | marketed | Progesterone receptor antagonist | Progesterone receptor (PR) | Reproductive Health / Gynecology |
Therapeutic area mix
- Reproductive Health / Gynecology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for China Resources Zizhu Pharmaceutical Co., Ltd.:
- China Resources Zizhu Pharmaceutical Co., Ltd. pipeline updates — RSS
- China Resources Zizhu Pharmaceutical Co., Ltd. pipeline updates — Atom
- China Resources Zizhu Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). China Resources Zizhu Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/china-resources-zizhu-pharmaceutical-co-ltd. Accessed 2026-05-17.